Thus, we hypothesized that EVEs decrease skin inflammation by reducing HMGB1, S100A8, and the TLR4/NF-κB/NLRP3 inflammasome pathway, which eventually decreases TPA-induced skin inflammation. The gene discussed is TLR4; the disease is dermatitis.